AOD9604
Targeted fragment of human growth hormone (hGH 177-191) retaining specific lipolytic activity.
Open AOD9604 in the 3D analyzerAnalytical specification
| Empirical formula | C78H123N23O23S2 |
|---|---|
| Molecular weight | 1817.1 g/mol |
| Isoelectric point (pI) | 4.56 |
| Assay purity (HPLC) | 99.60% |
| Retention time | 5.10 min |
| Peak area / height | 11100 / 900 |
| Reference batch | AO-2026-Z45 |
| Research category | Metabolic & Weight Management |
| Amino-acid sequence | Y-R-E-E-D-D-P-S-F-F-C-F-R-C-R-D-N-S |
Research characteristics
Lipolysis Activation
Triggers fat mobilization mechanisms
No IGF-1 Spike
Does not affect plasma insulin levels
Bone Repair
Fosters cellular cartilage regeneration
Safety Index
Well-tolerated in cellular trial labs
Reconstitution
Use the interactive reconstitution calculator to convert vial size (mg), bacteriostatic water volume (ml) and target dose (mcg) into a syringe draw on a standard 100-unit insulin syringe. Open the dosage calculator.
Related metabolic & weight management compounds
Retatrutide (Reta)
Next-generation triple receptor agonist (GLP-1, GIP, GCGR) driving advanced metabolic homeostasis.
Tirzepatide (Tirze)
Dual GIP and GLP-1 receptor agonist targeting glucose homeostasis and body composition dynamics.
Semaglutide
Established GLP-1 receptor agonist mimicking natural incretin hormones with modified clearance curves.
Liraglutide
Acylated human glucagon-like peptide-1 analog designed for clinical metabolic investigation models.
Cagrilintide
Long-acting amylin analogue targeting dual pathways in conjunction with incretin receptor systems.
Mazdutide
Novel dual GLP-1R/GCGR agonist targeting lipid elimination and cellular thermodynamic burn.